Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Jennings, Danna | Eberly, Shirley | Oakes, David | Seibyl, John | Marek, Ken | Shoulson, Ira | the Parkinson Study Group PRECEPT Investigators
Affiliations: Institute for Neurodegenerative Disorders, New Haven, CT, USA | Department of Biostatistics and Computational Biology, University of Rochester, Rochester, NY, USA | Program for Regulatory Science & Medicine (PRSM), Georgetown University, Washington, D.C., USA
Note: [] Correspondence to: Danna Jennings, MD, Institute for Neurodegenerative Disorders, 60 Temple Street, Suite 8B, New Haven, CT 06510, USA. Tel.: +1 203 401 4349; Fax: +1 203 401 4301; E-mail: [email protected]
Abstract: Background: Little is known about the impact of providing individual research results to clinical trial participants or the impact of sharing such data. Objective: The objective of this follow-up study was to evaluate the desire of participants for learning their imaging results and the impact of this information on their perception of their PD diagnosis and care. Methods: The Parkinson Research Examination of CEP-1347 Trial (PRECEPT) evaluated the experimental treatment CEP-1347 obtaining dopamine transporter imaging at baseline and 22 months as a secondary outcome. Dopamine transporter imaging and results were categorized as ‘dopamine transporter deficit’, ‘no dopamine transporter deficit’ or ‘indeterminate.’ Self-administered surveys were provided on three occasions to subjects who chose to learn their dopamine transporter imaging results: prior to receiving imaging data, immediately following receipt of imaging information, and three months following image disclosure. Results: 656/777 subjects (84.4%) consented to receive their individual imaging data, comprising overall result categories of 86.3% ‘dopamine transporter deficit’, 10.4% ‘no dopamine transporter deficit’, and 3.4% ‘indeterminate.’ 99.6% of subjects believed their decision to receive data was correct. Following disclosure of imaging results, 97% of the ‘dopamine transporter deficit’ and ‘indeterminate’ subjects believed they had Parkinson disease compared with 34% of ‘no dopamine transporter deficit’ subjects. About 45% of participants reported that learning individual imaging data resulted in improved understanding of their diagnosis. Conclusion: The majority of research participants chose to learn their individual dopamine transporter imaging results and were satisfied with their decision. Disclosure of imaging information resulted in improved understanding of parkinsonian symptoms in nearly half of subjects, and less belief among ‘no dopamine transporter deficit’ subjects that they had a diagnosis of Parkinson disease.
Keywords: Dopamine transporter, single photo emission-computed tomography, Parkinson's disease
DOI: 10.3233/JPD-140383
Journal: Journal of Parkinson's Disease, vol. 4, no. 4, pp. 629-638, 2014
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]